Publication:
Clinical impact of depression and anxiety in patients with non-cystic fibrosis bronchiectasis

dc.contributor.authorCEYHAN, BERRİN
dc.contributor.authorKOCAKAYA, DERYA
dc.contributor.authorBALCAN, MEHMET BARAN
dc.contributor.authorERYÜKSEL, SEMİHA EMEL
dc.contributor.authorOLGUN YILDIZELİ, ŞEHNAZ
dc.contributor.authorsBekir, Melahat; Kocakaya, Derya; Balcan, Baran; Olgun Yildizeli, Sehnaz; Eryuksel, Emel; Ceyhan, Berrin
dc.date.accessioned2022-04-25T00:11:45Z
dc.date.accessioned2026-01-11T08:32:38Z
dc.date.available2022-04-25T00:11:45Z
dc.date.issued2020
dc.description.abstractIntroduction: Bronchiectasis is a chronic suppurative disease characterized by abnormal bronchial dilatation. The nature of bronchiectasis may have negative impact on psychological status, however it is poorly studied in relation to clinical indices, particularly the severity of disease. Primary aim of this study is to detect depression and anxiety in patients with non-cystic fibrosis bronchiectasis and to evaluate its relationship with disease severity indexes. Materials and Methods: Ninety (male/female= 37/53; median age 45 years) stable non-cystic fibrosis bronchiectatic adult patients were enrolled into this study. Dyspnea scores, number of exacerbations and hospital admissions within the last year, body-mass index, pulmonary function tests, sputum cultures, bronchiectasis disease severity indexes (BSI and FACED) were assessed. Anxiety and depression were evaluated by using the Turkish version of the hospital anxiety and depression scale questionaire. Results: Anxiety was diagnosed in 30% of patients and depression was diagnosed in 41% of the participants. Female participants had significantly higher rates of depression (55% vs. 22%; p= 0.002). Exacerbation rates within the last year were higher among the subjects with anxiety, moreover, patients with depression had shorter duration of disease. 851 and FACED severity indexes increased with longer duration of disease (5.6 +/- 5.0 yrs in mild group vs. 10.1 +/- 9.2 yrs in moderate-to-severe group, p= 0.035 and 5.7 +/- 5.4 yrs in mild group vs. 12.1 +/- 9.7 yrs in moderate-to-severe group, p= 0.001, respectively), however, anxiety and depression were not related with BSI and FACED severity indexes. Conclusion: Patients with non-cystic fibrosis bronchiectasis have an increased risk for depression and anxiety. Duration of disease and higher exacerbation rate are related with psychological status and indexes increased with longer duration of disease. Lady detection and taking the necessary measures to improve the psychological state is necessary for the overall management of these patients.
dc.identifier.doi10.5578/tt.69348
dc.identifier.issn0494-1373
dc.identifier.pubmed32755109
dc.identifier.urihttps://hdl.handle.net/11424/263961
dc.identifier.wosWOS:000556543200003
dc.languageeng
dc.publisherTURKISH ASSOC TUBERCULOSIS & THORAX
dc.relation.ispartofTUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDepression
dc.subjectanxiety
dc.subjectbronchiectasis
dc.subjectSEVERITY
dc.subjectSTANDARDIZATION
dc.subjectOUTPATIENTS
dc.titleClinical impact of depression and anxiety in patients with non-cystic fibrosis bronchiectasis
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage111
oaire.citation.issue2
oaire.citation.startPage103
oaire.citation.titleTUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
oaire.citation.volume68

Files